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Background
Central nervous system (CNS) complications after allogeneic hematopoietic stem cell 
transplantation (HSCT) have not been well characterized in the pediatric population. 
Methods
We retrospectively analyzed data of 202 consecutive children who underwent allogeneic 
HSCT (60 from matched related donors, 9 from mismatched related donors, and 133 from 
unrelated donors) at Asan Medical Center between 1998 and 2009. 
Results
Twenty-seven children (13.5%) developed CNS complications within 6 months after 
HSCT. Calcineurin inhibitor (CNI)-associated neurotoxicity was the most common CNS 
complication (n=16), followed by CNS infection (n=2), cerebrovascular events (n=2), 
thrombotic microangiopathy-associated events (n=2), metabolic encephalopathy 
(n=2), irradiation/chemotherapy injury (n=1), and encephalopathy/myelopathy of un-
known causes (n=2). Univariate analysis showed that a transplant from an alternative 
donor and the occurrence of acute graft-versus-host disease (GVHD) (＞grade 2) were 
associated with a significantly increased risk of CNS complications. In the multivariate 
analysis, acute GVHD ＞grade 2 was identified as an independent risk factor for early 
CNS complications. The 5-year overall survival rate was significantly lower in patients 
with CNS complications (52.1% vs. 64.9%, P=0.014), whereas CNI-associated neuro-
toxicity did not affect the survival outcome.
Conclusion
CNS complications are frequent among children undergoing HSCT, contributing to early 
death after transplant. More attention should be paid to the development of CNS compli-
cations for recipients of alternative donor transplants and patients with severe acute 
GVHD who are at increased risk for CNS complications.
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INTRODUCTION
  Hematopoietic stem cell transplantation (HSCT) has been 
widely performed for various genetic and acquired as well 
as malignant and non-malignant diseases. However, highly 
intensified conditioning regimens can lead to serious morbid-
ity and mortality such as major organ dysfunction, life- 
threatening infections, and bleeding. In allogeneic HSCT, 
graft-versus-host disease (GVHD) constitutes a major addi-
tional source of transplant-related morbidity and mortality. 
Neurological complications are also significant clinical prob-
lems in the posttransplant period in allogeneic HSCT recipients.
  Significant neurological events have been variably re-
ported to range from 11% to 59% of HSCT recipients and 
to be associated with a mortality rate up to 10% of patients 
[1-4]. Cyclosporine (CsA)-related neurotoxicity or metabolic 
disturbances have been reported to be one of the most com-
mon neurological complications [2, 3, 5-7], whereas in autop-
sy studies, cerebrovascular disorders were the primary diag-
nosis in the neuropathological examination [8]. Despite the 
fact that neurological complications after allogeneic HSCT Korean J Hematol 2010;45:164-70.
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represent a major cause of morbidity and mortality, they 
have not been clearly described, especially in the pediatric 
population. Furthermore, the risk factors for neurological 
complications and the impact of neurological complications 
on posttransplant survival have been inconsistently 
described.
  We evaluated the incidence of significant neurological 
complications occurring in the early period after HSCT by 
focusing on the central nervous system (CNS) complications. 
The main objectives were to describe the various types of 
CNS complications, the impact of different risk factors, and 
the survival outcomes according to CNS complications in 
allogeneic HSCT for children. 
MATERIALS AND METHODS
1. Patients
  This study included 202 consecutive patients who under-
went allogeneic HSCT for malignant and non-malignant 
hematologic disorders and inherited disorders at Asan 
Medical Center (Seoul, Korea) between June 1997 and August 
2009. All patients were younger than 20 years at the time 
of transplantation. Data on demographics, underlying dis-
eases, CNS involvement of the primary disease, CNS irradi-
ation before treatment, transplant-related factors, and clin-
ical course after transplantation were collected retro-
spectively from the transplant database and electronic medi-
cal records of Asan Medical Center.
  Histocompatibility of all donor-recipient pairs was de-
termined by serology for human leukocyte antigens (HLA)- 
A, -B, and -DRB1. Patients and donors were typed for HLA-A, 
-B, and -DRB1 by serological methods between 2000 and 
2002 and by high-resolution molecular typing since 2003. 
A fully matched sibling was defined as a 6/6 match on all 
A, B, and DRB1 loci. Unrelated donors were 6/6-matched, 
8/8 allele-matched, or mismatched at a single antigenic or 
allelic locus.
2. CNS complications
  Data were retrieved on clinically significant CNS compli-
cations occurring within the first 6 months following alloge-
neic HSCT. For the purpose of this study, only toxicities 
of grade 3 or 4 according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 3.0 were 
considered. The following complications were defined as 
clinically significant: seizures, altered level of consciousness, 
visual disturbances, involuntary movements, motor/sensory 
deficits, cranial nerve palsies, and severe headaches. CNS 
relapse and CNS events that occurred following relapsed 
disease were not included. Non-repetitive seizures associated 
with busulfan were also excluded.
  The etiology of CNS complications was determined by 
clinical history, symptoms, and microbiological, electro-
physiological, and radiological characteristics. CNS compli-
cations were grouped into 6 categories, namely, calcineurin 
inhibitor (CNI)-associated neurotoxicity, cerebrovascular 
events, metabolic encephalopathy (associated with renal fail-
ure, liver failure, or electrolyte imbalance), CNS infection, 
thrombotic microangiopathy (TMA)-associated neurological 
manifestations, and radiotherapy/chemotherapy toxicity. 
CNI-associated neurotoxicity was defined as any acute ence-
phalopathy that could be related to the administration of 
CsA or tacrolimus based on the exclusion of other causes. 
CNI-associated neurotoxicity was characterized by seizures, 
changes in the mental status, involuntary movement, or visu-
al disturbance that might be associated with hypertension. 
The identification of CNI-associated neurotoxicity was sup-
ported by the clinical history, electrophysiological, and radio-
logical findings. Trough levels of CsA and tacrolimus at the 
onset of CNS complications were also reviewed.
3. Conditioning regimen and GVHD prophylaxis
  The conditioning regimen for each patient depended on 
the underlying disease, type of donor and graft, and comor-
bidities. Myeloablative regimens consisted of total body irra-
diation (TBI, 6 fractions of 2 Gy each) or busulfan (16 mg/kg); 
most patients also received cyclophosphamide (120-200 
mg/kg). If busulfan was administered, prophylactic pheny-
toin (5 mg/kg/day) was administered in children older than 
10 years. Reduced-intensity regimens were based on fludar-
abine (150 mg/m
2) in variable combinations with busulfan 
(8 mg/kg), cyclophosphamide (120 mg/kg), low-dose TBI 
(2 Gy), or antithymocyte globulin (ATG). 
  GVHD prophylaxis consisted of CsA combined with one 
of the followings: methotrexate, corticosteroid, or mycophe-
nolate mofetil (MMF). The target serum concentration of 
CsA was 150-300 ng/mL. Tacrolimus was used for the patients 
with GVHD who were unsuccessfully controlled with CsA. 
The target serum concentration for tacrolimus was between 
5-15 ng/mL. Acute GVHD was graded according to the stand-
ard criteria [9]. Patients were considered evaluable for acute 
GVHD, if they survived after engraftment.
4. Statistical analysis
  The cumulative probability of developing CNS complica-
tions within 6 months after transplant was determined using 
the Kaplan-Meier method. Univariate analysis was per-
formed to determine the significant risk factors for develop-
ing CNS complications. When the number of events was 
not large enough, the Fisher’s exact test was used for catego-
rical variables. Cox proportional hazard model was used on 
multivariate analysis to determine the impact of the various 
independent risk factors. P-values less than 0.05 were consid-
ered statistically significant. Statistical analyses were per-
formed using SPSS (Statistical Package for the Social Science, 
version 15.0, SPSS Inc, Chicago, IL, USA) and GraphPad 
Prism (version 5.01, GraphPad Software Inc, La Jolla, CA, 
USA).Korean J Hematol 2010;45:164-70.
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Table 1. Continued.
Characteristics
Patients 
with CNS 
complications 
(n=27)
N (%)
Patients 
without CNS 
complications 
(n=175)
N (%)
Total 
(n=202)
N (%)
P
Acute GVHD ＜0.001
No 5 (4.5) 107 (95.5) 112 (55.4)
Grade 1-2 6 (10.7) 50 (89.3) 56 (27.7)
Grade 3-4 15 (51.7) 14 (48.3) 29 (14.4)
NA 1 (20.0) 4 (80.0) 5 (2.5)
a)Other BMF included pure red cell anemia and Kostmann syn-
drome, 
b)Immunodeficiency included chronic granulomatous di-
sease, severe combined immunodeficiency, Omenn syndrome, 
and Wiskott-Aldrich syndrome, 
c)Storage disease included Krabbe 
disease and adrenoleukodystrophy.
Abbreviations: CNS, central nervous system; AML, acute myeloid 
leukemia; ALL, acute lymphoblastic leukemia; BAL, biphenotypic 
acute leukemia; CML, chronic myelogenous leukemia; JMML, 
juvenile myelomonocytic leukemia; MDS, myelodysplastic syn-
drome; HLH, hemophagocytic lymphohistiocytosis; SAA, severe 
aplastic anemia; BMF, bone marrow failure; TBI, total body 
irradiation; ATG, antithymocyte globulin; MTX, methotrexate; 
MMF, mycophenolate mofetil; GVHD, graft-versus-host disease; 
NA, not applicable.
Table 1. Patient characteristics and risk factors for development of 
central nervous system complications within 6 months after 
hematopoietic stem cell transplant.
Characteristics
Patients 
with CNS 
complications 
(n=27)
N (%)
Patients 
without CNS 
complications 
(n=175)
N (%)
Total 
(n=202)
N (%)
P
Median age,  yr (range) 6.9
(0.7-16.5)
7.3
(0.6-18.4)
7.1 
(0.6-18.4)
0.90
Sex 0.70
Male 18 (14.1) 110 (85.9) 128 (63.4)
Female 9 (12.2) 65 (87.8) 74 (36.7)
Diagnosis
AML 4 (4.5) 84 (95.5) 88 (43.6)
ALL 6 (15.0) 34 (85.0) 40 (19.8)
BAL 1 (14.3) 6 (85.7) 7 (3.5)
CML 2 (18.2) 9 (81.8) 11 (5.4)
JMML 1 (50.0) 1 (50.0) 2 (1.0)
MDS 4 (30.8) 9 (69.2) 13 (6.4)
HLH 1 (16.7) 5 (83.3) 6 (3.0)
SAA 4 (19.0) 17 (81.0) 21 (10.4)
Fanconi anemia 2 (50.0) 2 (50.0) 4 (2.0)
BMF, other
a) 1 (33.3) 2 (66.7) 3 (1.5)
Immunodeficiency
b) 1 (25.0) 3 (75.0) 4 (2.0)
Storage disease
c) 0 3  (100) 3  (1.5)
CNS involvement 0.93
Yes 4 (12.9) 27 (87.1) 31 (15.3)
No 23 (13.5) 148 (86.5) 171 (84.6)
Type of donor 0.01
Matched related  2 (3.3) 58 (96.7) 60 (29.7)
Mismatched related  1 (11.1) 8 (88.9) 9 (4.5)
Unrelated  24 (18.0) 109 (82.0) 133 (65.8)
Source of stem cells 0.06
Bone marrow 12 (9.8) 110 (90.2) 122 (60.4)
Peripheral blood 8 (15.4) 44 (84.6) 52 (25.7)
Cord blood 7 (25.0) 21 (75.0) 28 (13.4)
Prior cranial irradiation 0.74
Yes 3 (15.0) 17 (85.0) 20 (8.4)
No 24 (13.2) 158 (86.8) 182 (91.6)
Conditioning regimen 0.25
Myeloablative 21 (12.2) 151 (87.8) 172 (85.1)
Reduced intensity 6 (20.0) 24 (80.0) 30 (14.9)
Use of high-dose TBI  0.39
Yes 7 (17.5) 33 (82.5) 40 (19.8)
No 20 (12.3) 142 (87.7) 162 (80.2)
Use of ATG 0.15
Yes 10 (19.2) 42 (80.8) 52 (25.7)
No 20 (11.3) 130 (88.7) 150 (74.3)
Use of fludarabine 0.13
Yes 6 (23.1) 20 (76.9) 26 (12.9)
No 21 (11.9) 155 (88.1) 176 (87.1)
Use of busulfan 0.18
Yes 15 (10.9) 123 (89.1) 138 (68.3)
No 12 (18.8) 52 (81.3) 64 (31.7)
GVHD prophylaxis 0.17
CsA+MTX 18 (11.0) 145 (89.0) 163 (80.7)
CsA+steroid 4 (23.5) 13 (76.5) 17 (8.4)
CsA+MMF 3 (21.4) 11 (78.6) 14 (6.9)
CsA 1 (20.0) 4 (80.0) 5 (2.5)
NA 1 (33.3) 2 (66.6) 3 (1.5)
RESULTS
1. Patient characteristics
  The clinical characteristics of the 202 patients (128 men, 
74 women) are summarized in Table 1. The median age 
at transplant was 7.1 years (range, 0.6-18.4 years). Sixty 
patients (29.7%) received HSCT from matched related donors 
(MRDs), 9 (4.5%) from mismatched related donors, which 
included 4 haploidentical mothers, and 133 (65.8%) from 
unrelated donors. Stem cell sources were bone marrow (BM) 
in 122 patients (60.4%), peripheral blood (PB) after mobi-
lization with granulocyte colony-stimulating factor in 52 
(25.7%), and cord blood stem cells in 28 (13.4%). The median 
follow-up after transplant was 60 months (range, 7-154 
months). 
2. CNS complications
  CNS events occurred in 27 children at a median of 31 
days after transplantation (range, 0-155 days) (13.5%, [95% 
confidence interval [CI]: 5.2-25.6]) (Fig. 1). Neurological 
symptoms included seizures in 15 patients (56%), altered 
level of consciousness in 12 (44%), severe headache in 6 
(22%), motor weakness in 2 (7%), paresthesia and sensory 
deficit in 1 (4%), tremor in 1 (4%), and visual disturbance 
in 1 (4%). The etiologies of CNS events were CNI-associated 
neurotoxicity in 16 children (59%), cerebrovascular events 
in 2 (7%), CNS infection in 2 (7%), TMA-associated neuro-
logical manifestations in 2 (7%), metabolic encephalopathy 
in 2 (7%), irradiation/chemotherapy toxicity in 1 (4%), ence-
phalopathy of unknown cause in 1 (4%), and myelopathy 
of unknown cause in 1 (4%) (Table 2).Korean J Hematol 2010;45:164-70.
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Fig. 1. The cumulative incidence of central nervous system com-
plications according to different types of donor within 6 months 
posttransplant. CI, confidence interval; HSCT, hematopoietic stem cell 
transplantation.
Table 2. Number and type of central nervous systemcomplications
according to the type of donor.
Type of 
complication
Type of donor
Total,
n=202
(%)
Matched 
related,
n=60 (%)
Mismatched
related,
n=9 (%)
Unrelated,
n=133 
(%)
CNI neurotoxicity 1 (1.7) 1 (11.1) 14 (10.5) 16 (7.9)
Cerebrovascular  1 (1.7) 0 1 (0.8) 2 (1.0)
Infection 0 0 2 (1.5) 2 (1.0)
TMA-associated 0 0 2 (1.5) 2 (1.0)
Metabolic 0 0 2 (1.5) 2 (1.0)
RT/chemotherapy 0 0 1 (0.8) 1 (0.5)
Unknown 0 0 2 (1.5) 2 (1.0)
Total 2 (3.3) 1 (11.1) 25 (18.8) 27 (13.5)
Abbreviations: CNI, calcineurin inhibitor; TMA, thrombotic micro-
angiopathy; RT, radiotherapy.
Fig. 2. Kaplan-Meier plots of overall survival in patients with and without CNS complications (A) and CNI neurotoxicity (B) within 6 months 
posttransplant. CNS, central nervous system; CNI, calcineurin inhibitor; HSCT: hematopoietic stem cell transplantation.
  The incidence of CNS complications in the alternative 
donor group (including mismatched/haploidentical related 
and unrelated donors) was significantly higher than that 
in the MRD group (18.5% vs. 3.4%, P=0.007) (Fig. 1). Of 
the 27 patients with CNS complications, 14 (52%) died be-
tween 4 days and 72 months (median, 4.7 months) after 
HSCT, and at a median of 35 days (range, 4 days-71 months) 
following CNS complications. The death of 4 patients was 
considered a direct result of CNS complications: cere-
brovascular events in 2 patients and CNS infection in 2. 
The remaining 10 patients died of other transplant-related 
causes: sepsis in 6, veno-occlusive disease in 1, acute GVHD 
in 1, pulmonary hemorrhage in 1, and sudden asphyxia in 
1. Mortality due to CNS complications represented 5.4% 
of all deaths following HSCT. The 5-year overall survival 
(OS) rate was significantly lower in patients who developed 
CNS complications within 6 months of transplant (52.1% 
vs. 64.9%, P=0.014). With regard to CNI-associated neuro-
toxicity, however, the 5-year OS rate was not significantly 
different between the groups of patients with and without 
CNI-associated neurotoxicity (74.0% vs. 62.1%, P=0.79) (Fig. 
2).
3. CNI-associated neurotoxicity
  Of the 16 patients with CNI-associated neurotoxicity, 15 
patients were alternative donor HSCT recipients (14 un-
related and 1 haploidentical), and 1 patient received the 
transplant from a MRD. The incidence of CNI-associated 
neurotoxicity in the unrelated donor HSCT recipients was 
significantly higher than that in the MRD HSCT recipients 
(10.5% vs. 1.7%, P=0.007). CsA was a potential etiologic 
agent in 12 patients and tacrolimus in 4. Twelve out of 
16 patients (75.0%) had acute GVHD and, of note, 10 of 
them were among the 29 patients who had acute GVHD Korean J Hematol 2010;45:164-70.
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Table 3. Multivariate regression analysis for central nervous 
system complications within 6 months after hematopoietic stem 
cell transplant.
Variable Comparison Odds ratio 95% CI P
Grade of 
acute 
GVHD
GVHD grade 0 1
GVHD grade 1-2 1.65 0.48-5.68 0.43
GVHD grade 3-4 11.96 3.96-36.11 ＜0.001
Abbreviations: GVHD, graft-versus-host disease; CI, confidence
interval.
higher than grade 2, and 2 were among the 56 with GVHD 
grade 1 or 2 (P＜0.001). 
  Neurological symptoms of CNI toxicity were accompanied 
with hypertension at the time of CNS events in 12 patients 
(75%). Corticosteroid therapy was used in combination with 
CNI at the time of CNS events in 13 patients (81%). Neuro-
imaging was performed in all patients (9 with computed 
tomography (CT) and magnetic resonance imaging (MRI), 
4 with CT only, and 3 with MRI only). MRI revealed typical 
white-matter lesions with occipital predominance consistent 
with posterior reversible encephalopathy syndrome (PRES) 
in 4 patients, focal cortical/subcortical lesions without topical 
preponderance in 6, signal abnormalities in the prechiasmatic 
optic nerve in 1, which suggested optic neuropathy, and 
nonspecific atrophic changes in 1. The CT scans were not 
informative enough because focal abnormalities that corre-
lated with the MRI findings were only seen in 3 of 13 
patients examined by CT, and 5 CT scans did not reveal 
abnormalities that were detected by MRI.
  When symptoms appeared, CsA and tacrolimus levels were 
within the target range in 10 patients and beyond it in 
6. In addition to supportive care, the initial management 
of CNI-associated neurotoxicity consisted of the change in 
medication (n=7), dose reduction (n=7), discontinuation for 
a short period and resumption at a lower dose (n=1), and 
discontinuation (n=1). None of these patients died of a direct 
consequence of CNI-associated neurotoxicity. Of the 11 pa-
tients whose neuroimaging showed focal abnormalities, 7 
patients recovered leaving no neurological sequelae with 
complete resolution of the focal lesions on MRI, 2 developed 
intractable seizures even after their MRI abnormalities were 
resolved, and the remaining 2 died of other transplant-related 
causes. Of the 5 patients who did not have proven abnormal-
ities on neuroimaging, 2 patients developed Lennox-Gastaut 
syndrome (1 patient showed bilateral hippocampal atrophy 
on MRI performed 6.7 years after HSCT, and the other had 
complications due to hypoxic brain injury after resuscitation 
from hemorrhagic shock), while the remaining 3 died of 
other transplant-related causes. 
4. Risk factors
  The analysis of the risk factors for developing early CNS 
complications included gender, age at HSCT, diagnosis, CNS 
involvement, CNS radiotherapy, type of donor and stem 
cell source, intensity of the conditioning regimen, treatment 
with TBI, fludarabine, busulfan, or ATG, GVHD prophylaxis, 
and occurrence and severity of acute GVHD (Table 1). In 
the univariate analysis, the type of donor for HSCT (matched 
related vs. mismatched related or unrelated, P=0.01) and 
the occurrence of acute GVHD (P＜0.001) were associated 
with an increased risk of CNS complications within 6 months 
after transplantation. The stem cell source tended to be asso-
ciated with an increased risk of CNS complications with 
borderline significance (P=0.06). When factors with a P＜0.2 
were evaluated in the multivariate analysis, grade 3 or 4 
of acute GVHD was shown to be an independent prognostic 
factor for the risk of early CNS complications (odds ratio 
[OR]=11.96, [95% CI: 3.96-36.11], P＜0.001) (Table 3).
DISCUSSION
  The cumulative incidence of CNS complications within 
6 months after HSCT was 13.5% and the mortality rate 
as a direct result of CNS complications was 5.4% of all deaths 
following HSCT. This result indicates that CNS complications 
represent a significant clinical problem among children un-
dergoing allogeneic HSCT. The significant risk factors for 
early CNS complications were alternative (mainly unrelated) 
donor transplant, and acute GVHD higher than grade 2. 
Cord blood as a stem cell source was a risk factor with 
borderline significance. 
  Our study focused on clinically significant neurological 
problems, which required immediate diagnostic effort and 
treatment. Because of the possible limitations of retrospective 
studies, it is likely that less severe and other functional prob-
lems might be underestimated. In fact, a prospective study 
that evaluated neurological, neuropsychological, and neuro-
radiological abnormalities, including clinically less sig-
nificant problems, reported that 47% of the patients devel-
oped new neurological abnormalities after allogeneic HSCT 
[10]. Our observation of 13.5% incidence is comparable to 
other large studies, which reported an incidence of significant 
neurological complications between 9.7% and 15.8% in pe-
diatric HSCT [1, 3, 4]. In contrast to observational studies, 
an autopsy study revealed that neuropathological findings 
were detected in 90% of autopsies performed in bone marrow 
transplant (BMT) patients, which suggests that most patients 
with life-threatening illness will experience neurological 
events [8]. 
  Allogeneic transplants (in studies including both autolo-
gous and allogeneic transplantation), acute GVHD ＞ grade 
2, and unrelated donor transplant have been identified as 
significant risk factors for neurological complications in most 
of the previous studies. The use of TBI [3, 5], female gender 
[5], electrolyte imbalance [11], pretransplant viral status [11], 
and diagnosis of acute myeloid leukemia (AML) [4] or chronic 
myelogenous leukemia [12] have been inconsistently de-
scribed as possible risk factors by various authors. We found 
that alternative (mainly unrelated) donor transplants and 
grade 3-4 acute GVHD were significant risk factors related Korean J Hematol 2010;45:164-70.
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to CNS complications in allogeneic HSCT recipients, which 
confirms the observations made in other studies. Multivariate 
analysis showed that severe acute GHVD was an independent 
risk factor for the occurrence of CNS complications. In pa-
tients undergoing allogeneic transplantation, the use of im-
munosuppressive agents, such as CsA and tacrolimus, is an 
essential component in the control of GVHD. Patients who 
experience severe acute GVHD are predisposed to CNI-asso-
ciated neurotoxicity because they are usually managed with 
aggressive immunosuppression therapy. In addition, cortico-
steroids used during the treatment of GVHD may contribute 
to the development of neurological events [13]. Moreover, 
it has been reported that patients with severe GVHD tend 
to experience not only CNS complications associated with 
immunosuppressive drugs but also CNS infections or 
TMA-associated neurological events due to immunosu-
ppression [1, 14].
  Alternative donor transplantation, especially unrelated do-
nor transplantation, could have an impact on the develop-
ment of CNS complications due to its association with a 
high incidence of GVHD. Although the graft source has 
been inconsistently reported as a risk factor for the develop-
ment of CNS complications [4], our study showed that cord 
blood as a graft source was a significant risk factor for CNS 
complications compared to a BM stem cell graft (25% vs. 
9.8%). Cord blood recipients are more susceptible to in-
fectious complications and likely to be exposed to the risk 
of hemorrhagic complications due to delayed engraftment. 
  CNI- or CsA-associated neurotoxicity has been con-
sistently reported as the most frequent cause of neurological 
complications after transplantation in previous studies [2-5]. 
In our study, CNI-associated neurotoxicity was the most 
common neurological event with an incidence of 7.9% and 
10.5% among all enrolled patients and among 133 unrelated 
donor transplant recipients, respectively. Patients with 
CNI-associated neurotoxicity may have variable white-mat-
ter lesions with or without cortical involvement on MRI 
[15]. The previous studies reported that the incidence of 
PRES ranged between 5.9% and 7.2% in allogeneic HSCT 
patients receiving CNIs, which seems higher than our ob-
servation [5, 16, 17]. These results imply that more thorough 
neuroradiological evaluations could more effectively detect 
events of PRES. Although marked abnormalities can be de-
tected by CT, CT has a limited role in the detection of 
cerebral parenchymal lesions associated with CNI neuro-
toxicity. Thus, MRI should be performed early in the diag-
nostic evaluation of patients on CNIs who develop significant 
CNS events. In particular, 1 patient in our series developed 
optic neuropathy associated with CsA, which has been rarely 
reported as a neurotoxic side effect of CsA [18, 19]. Thus, 
optic side effects as well as PRES should be ruled out when 
patients during CsA therapy develop visual disturbance after 
HSCT. 
  Patients who develop seizures or encephalopathic features 
tend to have elevated blood pressure (BP) at the time of 
the CNS events. In this context, CNI-associated neurotoxicity 
could encompass patients who were historically thought to 
have hypertensive encephalopathy [20]. The serum levels 
of CsA or tacrolimus were slightly elevated in only 6 of 
16 patients with CNI-related toxicity at the time of CNS 
events, and did not increase far above the upper limit in 
any patient. It was suggested that genetic differences in the 
CsA metabolism might be related to CsA toxicity at the 
therapeutic blood levels in a case report [21]. In addition, 
the lack of a direct correlation between CsA levels and 
CsA-associated neurotoxicity was previously described [15, 
22]. These findings emphasize that therapeutic drug monitor-
ing cannot predict all adverse events associated with CNIs. 
Thus, recognition of prodromal signs such as tremulousness 
or headache, meticulous control of the BP, and correction 
of the electrolyte imbalance are important for the early de-
tection and prevention of CNI-associated toxicity.
  CNI-associated toxicity is known to be reversible after 
withdrawal of the drug [23]. However, irreversible cases 
have been reported in a few instances [24]. It is important 
to note that 4 patients developed intractable seizures later 
during the long-term follow-up despite the resolution of 
focal white-matter lesions in 2 patients and the absence 
of documented lesion at initial presentation in the other 
2. This result suggests that long-term results of CNI-asso-
ciated toxicity may not always be reversible, regardless of 
the resolution of the initial lesions on neuroimaging. In par-
ticular, 1 patient showed bilateral hippocampal atrophy on 
the follow-up MRI. Faraci et al. also reported 3 patients 
who developed intractable seizures with mesial temporal 
sclerosis on MRI after CsA-associated neurotoxicity [3]. This 
late complication might be associated with an unrecognized 
acute lesion on the hippocampus, since acute hippocampal 
lesions documented on MRI were reported as CNI-mediated 
neurotoxicity [25]. 
  Our data demonstrated a significantly reduced survival 
rate for patients with CNS complications. However, when 
the comparison was done between patients with and without 
CNI-associated toxicity, significant differences in the OS 
were not observed. These findings suggest that CNS compli-
cations, excluding fatal complications, such as cerebrova-
scular event and CNS infection, are not associated with 
long-term survival. Iguchi et al. also reported that significant 
differences in the long-term survival were not observed be-
tween children with and without neurologic complications, 
whereas adverse neurological events contributed to early 
death [1]. In contrast, Siegal et al. reported significantly 
reduced survival in patients with CNS complications as well 
as in those with PRES in their adult series [5]. GVHD has 
been reported to represent the primary cause of death follow-
ing CNI-associated neurotoxicity in the previous adult studies 
[5, 17]. However, our report showed that only 1 patient 
with CNI-associated toxicity died of a direct consequence 
of acute GVHD. The discrepancy between pediatric and adult 
studies might reflect differences in the susceptibility to 
GVHD between children and adults. Since discontinuation 
of CNI administration may cause poor prevention and man-
agement of GVHD resulting in significant mortality due 
to GVHD, decisions on the changes in the immunosu-Korean J Hematol 2010;45:164-70.
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ppressive agent should be made carefully in order to balance 
the control of GVHD and the management of CNI-associated 
neurotoxicity. 
  In conclusion, CNI-associated toxicity was the main cause 
of neurotoxicity in children receiving allogeneic HSCT, fol-
lowed by cerebrovascular events, infection, metabolic ence-
phalopathy, and TMA-associated neurological abnormalities. 
These results imply that more attention should be paid to 
the recognition of the development of CNS complications 
for recipients of alternative donor transplants (especially un-
related donor) and patients with severe acute GVHD, who 
are at a significantly increased risk of CNS complication. 
Immediate and comprehensive diagnostic work-up, espe-
cially neuroimaging, is required to detect neurological events 
in any patients presenting with neurological symptoms. 
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